Welcome to our dedicated page for BlackRock Health Sciences Trust SEC filings (Ticker: BME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BlackRock Health Sciences Trust's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BlackRock Health Sciences Trust's regulatory disclosures and financial reporting.
BME filed an N-CEN annual report that discloses operational information for its registered investment company, including securities lending activity, brokerage commissions and principal transaction volumes.
The report shows a monthly average value of portfolio securities on loan of $857,512.27 and securities lending net income of $15,085. Aggregate brokerage commissions paid during the reporting period were $339,015.19. Principal transaction records include a largest reported counterparty total value of $375,407,698.01.
BlackRock Health Sciences Trust (BME) filed its Form N-CSR for the fiscal year ended 12/31/2025, attaching the certified shareholder report and supplemental information covering distributions, portfolio summaries and strategy disclosures for BME and related BlackRock closed-end funds.
Key disclosures include a total per‑share cumulative distribution for BME of $3.145200 for the fiscal period (reported as 91% long‑term capital gains, 5% return of capital, 4% net income), fixed monthly distributions of $0.262100 per share, and a Board decision effective November 10, 2025 to remove the options writing strategy as a principal investment strategy.
BlackRock Health Sciences Trust portfolio manager Liu Xiang reported compensation-related transactions involving phantom shares and common stock. On January 30, 2026, Liu received 372.9639 phantom shares, each economically equivalent to one common share and payable in cash upon vesting. The filing also shows the exercise of previously granted phantom shares into 389.1035 common shares, followed by the disposition of those 389.1035 common shares at $41.87 per share, leaving no directly held common stock after the sale. Phantom share awards from 2023, 2024, 2025 and 2026 all vest in equal installments over three years.
BlackRock Health Sciences Trust portfolio manager Erin H. Xie reported a combination of phantom share awards and a stock sale. On January 30, 2026, 11,449.5087 shares of common stock were acquired through the exercise of derivative awards and then sold at $41.87 per share, leaving no directly held common stock.
Xie also received 6,379.1521 phantom shares, which are cash-settled units economically equivalent to common stock and vest in three annual installments, as described in prior and current phantom share grant footnotes.